Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Company Overview - Cabaletta Bio is a clinical-stage biotechnology company focused on engineered T cell therapies aimed at treating autoimmune diseases [1] - The company is headquartered in Philadelphia, PA [1] Product Development - The CABA™ platform includes two main strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody receptor T cells) [1] - The lead product candidate, CABA-201, is a fully human CD19-CAR T cell being evaluated in clinical trials for systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis [1] - The RESET™ clinical trials and the RESET-PV™ sub-study within the DesCAARTes™ clinical trial are key components of the product evaluation [1] - Multiple clinical-stage candidates are being developed under the CAART strategy, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis [1] Upcoming Events - Steven Nichtberger, M.D., CEO of Cabaletta Bio, will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024 [2]